ORP 100 S
Alternative Names: ORP-100; ORP-100S; Recombinant modified human thioredoxin 1 - OrPro Therapeutics; TheraduxLatest Information Update: 28 Jun 2024
At a glance
- Originator National Jewish Medical and Research Center
- Developer OrPro Therapeutics
- Class Anti-inflammatories; Antivirals; Recombinant proteins; Thioredoxins
- Mechanism of Action Thioredoxin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute radiation syndrome
- No development reported Bronchiectasis; Cystic fibrosis; Inflammation
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for preclinical development in Bronchiectasis in USA (Inhalation, Aerosol)
- 28 Jun 2024 No recent reports of development identified for preclinical development in Cystic-fibrosis in USA (Inhalation, Aerosol)
- 28 Jun 2024 No recent reports of development identified for research development in Inflammation in USA (Inhalation, Aerosol)